Showing results (71-80 of 3,590) with videos related to
Sort By:
Pageof 359
Journal of Viral Hepatitis|December 24, 2017
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infectionM S Sulkowski, J J Feld, E Lawitz, et al.Journal of Viral Hepatitis|December 24, 2017
Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysisM El Kassas, A L Funk, M Salaheldin, et al.Journal of Viral Hepatitis|January 30, 2018
Efficacy of generic oral directly acting agents in patients with hepatitis C virus infectionS Gupta, G Rout, A H Patel, et al.Journal of Viral Hepatitis|November 7, 2017
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4H L Y Chan, C J Chen, O Omede, et al.Journal of Viral Hepatitis|November 7, 2017
Estimating HCV disease burden-volume 4 (editorial)G J Dore, A Hatzakis, F Negro, et al.Journal of Viral Hepatitis|November 22, 2017
Trends in hepatitis C-related mortality in SwitzerlandO Keiser, F Giudici, B Müllhaupt, et al.Journal of Viral Hepatitis|December 23, 2018
Genomic variability of within-host hepatitis C variants in acute infectionChaturaka Rodrigo, Preston Leung, Andrew R Lloyd, et al.Journal of Viral Hepatitis|December 23, 2018
Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis BLiang Zhou, Xiaoyan Li, Xiaohui Huang, et al.Journal of Viral Hepatitis|December 15, 2018
Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infectionJulia Hengst, Andreas L Klein, Sebastian Lunemann, et al.Journal of Viral Hepatitis|November 18, 2006
Alpha-defensin increase in peripheral blood mononuclear cells from patients with hepatitis C virus chronic infectionA Aceti, M L Mangoni, C Pasquazzi, et al.Pageof 359